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PHARMACOTHERAPEUTIC STUDY OF ANTIRETROVIRAL  
THERAPY FOR HIV/AIDS PATIENTS AT THE FEDERAL  
MEDICAL CENTRE, OWO, ONDO STATE, NIGERIA 
 
ABSTRACT 
A 6-12 months retrospective study is made of HAART utilization in cases of HIV/AIDS 
patients at Federal Medical Centre, Owo, Nigeria. The objective to evaluate the rational 
pharmacotherapeutic approach to the management of the retroviral disease. Sixty two (62) 
antiretroviral drug-naive HIV/AIDS patients, which comprise of (19) 30.65% males with a 
mean age of 37.15±8.55 years and (43) 69.35% females with a mean age of 35.68±9.75 years 
case files are reviewed. The data used for this study was extracted from the clinical records 
of the Hospital.  Sixty six percent of the patients are at World Health Organization (WHO) 
clinical stage III or IV of the HIV disease at initiation of HAART and 35.70% of patients have 
baseline CD4 cell count ≤50 cells/µL. Stavudine/Lamivudine/Nevirapine is used as HAART 
first line regimen in 87.10% of the patients while 12.90% are prescribed 
Stavudine/Lamivudine/Efavirenz due to underlying TB infection. Three (3) patients switched 
their initial regimen while a patient had her regimen discontinued because of drug adverse 
effects. Evaluation of 35 patients for therapeutic response after a mean period of 9.07 months 
shows that, in 82.86% of patients, mean CD4 cell count increased from 96.70 ± 67.90 
cells/µL (median 104 cells/µL) at baseline to 267.60 ± 141 cells/µL (median 267 cells/µL). 
After a mean period of 9.07 months of HAART, there is a significant difference in the change 
in CD4 count among male and female patients there is no significant correlation between age 
and change in patients’ CD4 count and within female patients but there is a significant 
positive correlation between age and change in CD4 count within male patients. It is 
therefore concluded that rational use of HAART in patients with retroviral disease will lead 
to significant improvement in most patients’ immunological status and invariably quality of 
life.   
 
Keywords: Pharmacotherapeutics, HAART, HIV/AIDS, CD4 Count 
INTRODUCTION 
Acquired Immune Deficiency Syndrome or Acquired Immunodeficiency Syndrome (AIDS) 
is a disease of the human immune system caused by the human immunodeficiency virus 
(HIV) (Weiss, 1993; Sepkowitz, 2001). HIV causes AIDS by depleting CD4 T helper 
lymphocyte. This weakens the immune system and allows opportunistic infections. T 
lymphocytes are essential to the immune response and without them; the body cannot fight 
infections or kill cancerous cells. 
The CD4 count serves as the major clinical indicator of immunodeficiency in patients who 
have HIV infection. It is the most important factor in deciding whether to initiate 
antiretroviral therapy and opportunistic infection prophylaxis, and it is the strongest predictor 
of subsequent disease progression and survival according to clinical trials and cohort studies 
(Mellors et al, 1997; Egger et al, 2002). 
 Although AIDS was discovered in 1981 and HIV identified in 1983, it was not until 1985 
that the first two HIV cases were identified in Nigeria and were reported at an international 
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AIDS Conference in 1986 (Adeyi et al, 2006). By the end of 2008, the United Nations Joint 
Programme on HIV/AIDS (UNAIDS) report on Nigeria estimates that around 3.1 percent of 
adults between ages 15-49 are living with HIV/AIDS (UNAIDS, 2008).  
The initial strategy of health experts as regards combating the HIV/AIDS scourge was to 
focus on reducing the incidence of opportunistic infections that were shown to cause high 
morbidity and mortality rather than inhibiting the growth of the virus (Fee & Krieger, 1993). 
However, further studies on the pathogenesis of the disease as well as genetic basis of 
resistance yielded positive result in 1987 with the registration of zidovudine as the first 
antiretroviral agent by United States Food and Drug Administration (FDA) (Young, 1988). 
Since that time, studies into the area of HIV therapeutics has been growing (Burton, 2006). 
Antiretroviral drugs which are used for the treatment of HIV infection, essentially act by 
blocking the action of enzymes that are important for replication and functioning of the HIV 
(Palmisano & Vella, 2011).  
The primary goals driving the decision to initiate antiretroviral therapy are to reduce HIV-
related morbidity and prolong survival, improve quality of life, restore and preserve 
immunologic function, maximally and durably suppress viral load and prevent vertical HIV 
transmission (DHHS Panel on Antiretroviral Guidelines, 2008).  
In resource limited setting, initiation of antiretroviral therapy in adults and adolescents is 
dependent on WHO clinical staging and CD4 count (WHO, 1990). Thus: 
The WHO staging system of HIV/AIDS is as follows; 
Stage I: HIV Infection is asymptomatic, generalized lymphadenopathy. 
Stage ii: Weight loss less than 10% of bodyweight, fungal nail infection, herpes zoster, 
recurrent upper respiratory tract infections (URTIs) 
Stage iii: Weight Loss greater than 10%, unexplained chronic diarrhoea for longer than 
one month or fever, oral candidiasis/hairy leukoplakia, pulmonary TB, severe 
bacterial infections. 
Stage IV: AIDS defining illness: e.g. HIV wasting syndrome, PCP, brain 
toxoplasmosis’, candida oesophagitis, extra- pulmonary TB, CMV retinitis, 
Kaposi Sarcoma, non – Hodgkin’s lymphoma.  Performance score 4: 
bedridden greater than 50% of the day during the last month. 
 Nigeria’s national guideline endorses the WHO recommendations for initiating antiretroviral 
therapy (ART) (FMoHN, 2005). 
ART should be initiated in the following categories of patients.    
If CD4 testing is available: 
• WHO stage IV disease irrespective of CD4 cell count; 
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• WHO stage III disease with CD4 count <350/mm3; 
• WHO stage I or II disease with CD4 cell count <200/mm3. 
(Note: CD4 cell count <200/mm3 is believed to be associated with a state of 
immunosuppression) 
If CD4 testing is unavailable, 
• WHO stage IV disease irrespective of total lymphocyte count (TLC).  
• WHO stage III disease irrespective of TLC. 
• WHO stage II disease with a TLC ≤1200/mm3  
In parallel with the discovery of ARVs has been a rapid evolution of different strategies for 
optimizing their use (Detel et al, 1998). Current treatment for HIV infection consists of 
HAART. This has been highly beneficial to many HIV-infected individuals since its 
introduction in 1996 when the protease inhibitor-based HAART initially became available 
(Beck et al, 2004; Murphy et al, 2001). Current optimal HAART options consist of 
combinations (or “cocktails”) consisting of at least three drugs belonging to at least two types 
or “classes” of antiretroviral agents (DHHS Panel on Antiretroviral Guidelines, 2008). 
Typical regimens consist of two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) plus 
either a Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or a Protease Inhibitor 
(PIs) (DHHS Panel on Antiretroviral Guidelines, 2008).  
While there are many effective HAART regimens that are used to treat HIV/AIDS, the initial 
strategy must be based on proven potency, ease of administration, potential drug toxicities, 
pharmacokinetics, expense and availability.  
In Nigeria, the initial choice of dual NRTIs is typically limited to one or two options: 
stavudine (but currently stavudine is gradually being replaced with tenofovir because of 
peripheral neuropathy) plus lamivudine or zidovudine plus lamivudine (FMoHN, 2005). Both 
are said to be effective but their side effect profiles are different. In addition to dual 
nucleoside reverse transcriptase inhibitors, the third drug of a HAART regimen is a critical 
choice (Squires et al, 2004; Staszewski et al, 1999). The most common third drug added to a 
HAART regimen is a non-nucleoside reverse transcriptase inhibitor, either nevirapine or 
efavirenz (F van Leth et al, 2004). An effective alternative to the non-nucleoside approach is 
the addition of a protease inhibitor as the third drug in a HAART regimen. PIs based HAART 
are only used as second line regimens in Nigeria (FMoHN, 2005).  
The most effective and practical protease inhibitors to be considered for second line therapy 
include lopinavir/ritonavir (Kaletra®), indinavir with or without ritonavir, and atazanavir 
with or without ritonavir (WHO, 2006).  
A lot of challenges are being encountered by both patients and care providers in achieving the 
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goals of therapy. This is due to the fact that HIV/AIDS patients on antiretroviral drugs most 
often take other medications to treat either opportunistic infections or co morbidities 
(Antoniou & Lin-in Tseng, 2002). This condition which is referred to as poly pharmacy gives 
room for potential drug-drug interactions which may modify the expected therapeutic 
outcomes (Piscitelli & Gallicano, 2001). Another impediment to the realization of full 
benefits of HAART is patients’ non adherence usually resulting from drug adverse effects 
(O’Brien et al., 2003). Therefore, HAART regimen must be tailored towards individual 
patient needs if adequate therapeutic response is to be achieved at the end of therapy. 
In order to tackle the burden of HIV/AIDS in Nigeria, the Federal government in 
collaborations with International Donor Agencies started distributing free antiretroviral drugs 
to patients since 1996 in treatment centres (WHO, UNAIDS and UNICEF, 2008). However 
little is known about therapeutic endpoints of the drug intervention. The aim of this study 
therefore, was to determine the appropriateness or otherwise of the current treatment 
strategies in restoring immunological functions of HIV/AIDS patients among other goals of 
ART. It is believed that such evaluation would be useful because, it will either reinforced or 
call for a review of the current strategies.     
 
Materials and Methods 
A 6 to 12 month retrospective cohort study of sixty two (62) antiretroviral drug-naive patients 
who attended Federal Medical Centre, Owo HIV/AIDS clinic between the periods of June 
2006 to May 2007 and were offered HAART. The study was approved by Federal Medical 
Centre Owo, Ethical Review Committee (ERC). To be selected for the study, the patient had 
to be 13 years of age or older and completely antiretroviral drug-naive at the start of first-line 
HAART. The patient must have been on HAART for at least 6 months by May 2007. Data 
for patients were collected retrospectively using patient case files obtained from the Medical 
Records Department of the health Institution. The files contain information on patient 
characteristics (e.g. gender, age and weight), tests performed at initiation (Baseline) of ART 
and during the course of ART  (e.g. liver function test (LFT), CD4 cell count, full blood 
count and drug resistance testing), patient clinical status at the time of initiation of therapy 
(e.g. WHO clinical stage, concurrent disease and physical assessment), detailed treatment 
data (e.g. use of antiretrovirals, prophylactic medications against opportunistic infections, 
concurrent medications, dose frequency, start and stop dates and reasons for treatment 
change) and adverse effects data. The analysis of the collated data was carried out with the 
use of both descriptive and quantitative techniques. The descriptive technique involves the 
use of frequency table and bar chart, while the quantitative technique involved the use of non 
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parametric statistics Mann-Whitney U-test and Spearman Rank Correlation test (Bamgboye, 
2006).  
 
RESULTS 
Patient categorization based on 2006 WHO clinical staging system 
Sixty percent (60%) of the patients studied were at stage III of the WHO clinical stage of 
retroviral disease (mean CD4 count 87 cells/µL), 12.90% at stage I (mean CD4 count 114.88 
cells/µL), 20.97% at stage II (mean CD4 count 94.92 cells/µL) and 6.45% of patients were at 
stage IV (mean CD4 count 60 cells/µL) of the disease (Figure 1). 
 
PATIENT CD4 COUNT AT BASELINE.  
All the patients performed baseline CD4 count at the beginning of study, except 6 patients 
who had total lymphocyte count (TLC) performed due to non-availability of CD4 count 
determining machine at the time of entry into treatment (The machine was later acquired in 
November, 2006). The TLC values were <1200 cells/µL. The analysis of the patients baseline 
CD4 cell count showed a range of 4-278 cells/µL (mean 92 ± 61 cells/µL). About thirty five 
percent (35.71) of patients had CD4 cell count of ≤50 cells/µL signifying the stage of severe 
immunosuppression while <4% of patients had CD4 cell count of >200 cells/µL (Table 1). 
 
HAART REGIMEN USED AS FIRST LINE 
Stavudine/Lamivudine/Nevirapine was prescribed as first line regimen in 87.10% of patients 
while 12.90% had Stavudine/Lamivudine/Efavirenz as first line (Table 2). Other HAART 
regimen introduced during the course of patients’ management were 
Zidovudine/Lamivudine/Efavirenz and Abacavir/Zidovudine/Lamivudine. 
 
CO-INFECTION AND CO-MORBIDITIES REVIEWED. 
Candidiasis (11.30%), malarial (35.48%), pulmonary tuberculosis (13%), upper respiratory 
tract infections (14.52%) and others (14.52%) were the concurrent infections with HIV while 
hypertension (19.35%) was the only co-morbidity recorded (Table 3) 
 
CONCOMITANT DRUGS PRESCRIBED 
Concomitant drugs prescribed with ARVs, included Antibacterials (Amoxicillin/Clavunalate 
16.13%, Ciprofloxacin 12.90% and others 24.19%), Analgesics (paracetamol 17.74%, 
NSAIDS 8.06%, tramadol 9.68%), Antimalarials (Artesunate/SP 16.13%, chloroquine 8.06%, 
chloroquine/SP 14.52%, others 21%), chlorphenamine 37.10%, antihypertensives 
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(Amiloride/HCT 17.74%, captopril 19.35%, methyldopa 11.29%, Nifedipine 9.68%, others 
14.52%), metronidazole 19.35%, Bromazepam 11.29%, Fluconazole 9.68%, micronutrients 
and multivitamins (Heamatinics 100%, Neurovite forte 12.90%, pyridoxine 12.90%) and 
other drugs 66.13% (Table 4). 
 
DRUG INTERACTIONS BETWEEN CONCURRENT DRUGS AND ARVS 
There were the possibilities of drug-drug interactions between the following drugs. 
Fluconazole/nevirapine (9.68%), rifampicin/nevirapine (1.61%), isoniazid/stavudine (13%) 
and cotrimoxazole/lamivudine (100%). Table 5. 
 
DOCUMENTED DRUG ADVERSE EFFECTS 
The recorded adverse effects include pain (19.35%), diarrhoea (14.52%), weakness/fatigue 
(4.84%), hallucinations (1.61%), Headache (4.84%), Insomnia (11.29%), itching (20.97%), 
paraesthesia (9.68%), peripheral neuropathy (3.23%), rash (16.13%), Stevens Johnson 
syndrome (1.61%) and change in taste perception (1.61%). Table 6. 
 
Change in patients cd4 counts 6-12 months after initiation of HAART. 
Out of the 62 patients studied, 21 patients (33.87%) did not repeat CD4 count test 6-12 
months after initiation of HAART due to financial incapacitation of patients, 5 patients 
(8.07%) defaulted while a patient (1.61%) was referred. 35 patients (56.45%) who performed 
CD4 tests during follow-up visits after a mean period of 9.07 months have their data given in 
Table 7. The analysis of the CD4 count showed that all except 6 patients numbered 3, 4, 7, 
11, 18 and 28 (17.14%), had an increase of >50 cells/µL. Mean CD4 cell count of the patients 
increased from 98.40 ± 66.85 cells/µL (median 104 cells/µL) at baseline to 267.60 ± 141 
cells/µL (median 267 cells/µL) (p<0.01). 
 
DISCUSSION 
Out of sixty two (62) patients studied, 30.65% were males while 69.35% were females giving 
a male to female ratio of 1 to 2.3. This ratio seems to be in line with findings of a research on 
HIV/AIDS conducted in Ile-Ife Nigeria which reported a male to female ratio of 1 to 1.4 
(Akinola et al., 2004) .This is also in agreement with studies that reported that women are 
more susceptible to HIV-1 infection due to hormonal changes as a result of use of hormonal 
contraceptives, vaginal microbial ecology and physiology and a higher prevalence of sexually 
transmitted diseases (Lavreys et al., 2004).  
A majority of patients studied in the present work (72.59%) were within the age bracket of 
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21-40 years with a mean age of 35.20 ± 10.50 years. This finding corroborates with the 
Federal Ministry of Health year 2001 National HIV/Syphilis sentinel survey (FMoHN, 2001) 
which reported that over 70% of adults infected with HIV/AIDS in Nigeria falls within the 
age bracket of 15-34 years. This is the age range that corresponds considerably to years of 
sexual activity and economic productivity. The implication of this will be a growing number 
of AIDS orphans and a strong economic burden which could cripple the workforce of the 
country. 
According to the patient categorization based on 2006 WHO clinical staging system, the 
study showed that 66.14% of the patients belonged to stage III or IV. This implies that 
majority of the HIV patients did not promptly seek medical treatment until the disease had 
reached an advanced stage. This might be as a result of either ignorance of availability of free 
antiretroviral drugs or the fear of social discrimination and isolation which were usually 
meted to people identified to be living with HIV/AIDS. This finding is similar to Ghana HIV 
cohort study in which 78% of patients had disease classified as WHO stage III or IV (Collini 
et al., 2009). 
The present work also shows that patients studied had a baseline CD4 count ranging from 4 
to 278 cells/µL. About thirty five percent (35.71%) of patients had CD4 count of ≤50 
cells/µL signifying the stage of severe immunosuppression. This finding is in line with 
research conducted in New Delhi, India where CD4 count of <50 cells/µL was seen in 18.6% 
of patients studied (Guatam et al., 2008). All the patients studied were considered qualified 
for antiretroviral therapy based on their baseline CD4 count values and WHO clinical stage 
which is in line with the national guidelines on the use of antiretroviral drugs. 
Concerning pharmacotherapy, 87.10% of the patients were prescribed D4T/3TC/NEV as 
HAART first line regimen while the remaining 12.90% of patients who had concurrent TB 
infection were prescribed a combination of D4T/3TC/EFV as HAART first line regimen in 
accordance with the national guidelines. A patient had his regimen (EFV/D4T/3TC) changed 
to EFV/AZT/3TC due to severe peripheral neuropathy caused by stavudine while another 
patient was switched from NEV/D4T/3TC to all NRTIs regimen comprising of 
ABC/AZT/3TC because of resistance and non-availability of protease inhibitor-based second 
line regimen. However, this combination was inferior virologically to an efavirenz-based 
regimen and was generally not recommended (Gulick et al., 2004). 
As regards concurrent infections and co-morbidity recorded with the retroviral disease only 
tuberculosis (TB) required special consideration as to the choice of NNRTI to be selected as 
component of HAART and therefore, efavirenz was given priority over nevirapine because it 
can be co-administer with rifampicin which is a basic component of anti TB drug regimen 
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unlike nevirapine which interact significantly with rifampicin which might result in HAART 
therapeutic failure. However, a patient who had her efavirenz changed to nevirapine three (3) 
months into therapy because of drug-induced hallucinations defaulted before she could be 
evaluated. 
In the present study, different drugs were prescribed concurrently with ARVs to manage 
patients. Cotrimoxazole was prescribed for all the patients as prophylaxis against 
opportunistic infections in conformity with WHO guidelines which recommends the use of 
cotrimoxazole in all HIV infected patients irrespective of the CD4 count (WHO, 2006). Over 
50% of patients who were infected with malaria were treated with combination of 
antimalarials that contains sulfadoxine/pyrimethamine (SP). This was at variance to WHO 
recommendations that HIV patients infected with malaria and are already on cotrimoxazole 
prophylaxis should be treated with antimalarials other than SP because of the problem of 
cross-resistance (WHO, 2006). This work also revealed that patients with hypertension were 
prescribed an average of three antihypertensives. Combination of these drugs with the 
HAART regimen and opportunistic infection prophylactic drugs might result in non-
adherence due to high pill burden and barrage of adverse effects (Haider et al., 2009). 
 A thorough review of patients’ medication profile showed that nevirapine could have 
interacted with fluconazole in 9.68% of the patients thereby resulting in an increase risk of 
hepatotoxicity. Interaction between stavudine and isoniazid can result in aggravation of 
peripheral neuropathy as this combination was seen in 13% of the patients, although 25mg 
daily dose of pyridoxine was prescribed to alleviate the condition. The interaction problem 
that could have resulted from combination of lamivudine and cotrimoxazole was mitigated 
with the adjustment of cotrimoxazole dose to 960 mg daily. 
Drug adverse effects constitute major challenge to patient’s adherence to medications and 
among the most common reasons for switching or discontinuation of therapy (O’Brein et al., 
2003). In this present study, three patients had regimen switched because of adverse effects 
while a female patient had her HAART regimen discontinued due to serious adverse effect 
(Stevens Johnson syndrome). Generally, patients were able to tolerate their medications due 
to transient nature of most of the adverse effects reported. 
Concerning therapeutic response to HAART as measured by change in patients’ CD4 count, 
82.86% of patients recorded an increase of >50 cells/µL after 6-12 months period of therapy. 
An adequate CD4 response to HAART is defined as an increase in the range of 50-150 
cells/µL for first year of therapy and increases that average 50-100 cells/µL for subsequent 
years until a steady state is reached (Kaufmann et al., 2003). In the present study, it could be 
concluded that 82.86% therapeutic success was achieved 6-12 months after HAART. 
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In this study, there was a significant difference (p<0.01) in the change in CD4 count among 
male and female patients as female patients recorded higher CD4 count changes (mean CD4 
count increased from 108.5 ± 59.10 cells/µL to 303.5 ±130.30 cells/µL) when compared to 
their male counterparts (mean CD4 count increased from 81.31 ± 77.80 cells/µL to 206.85 ± 
142.42 cells/µL) 6-12 months after initiation of HAART. This finding was in line with the 
work of Thomas et al (2003) which reported greater CD4 cell count increases for women 
compared to men 6 months after HAART (Giordano et al., 2003). Also in this study, there 
was no significant correlation between patient’s age and change in CD4 count 6-12 months 
after initiation of therapy (p> 0.05). The present finding is contrary to the findings of 
Manfredi and Chiodo which reported significant correlation between patient’s age and CD4 
count after one year of HAART (Manfredi and Chiodo, 2000). However, there was a 
significant positive correlation (p< 0.05) between age and change in CD4 count within male 
patients but there was no significant correlation (p> 0.05) between age and change in CD4 
count within female patients. As regards baseline CD4 count value, there was a significant 
positive correlation (p< 0.05) between baseline CD4 count value and change in patients  CD4 
count among patients and also within female patients but there was no significant correlation 
between baseline CD4 count value and change in CD4 count within male patients (p> 0.05). 
In conclusion, this study has showed that rational use of HAART in the management of 
HIV/AIDS can lead to significant improvement in most patients’ immunological status and 
invariably quality of life. However, full benefits of HAART can only be realized, if patients 
report for treatment on time and adhere to prescribed drug therapy. 
 
 
RECOMMENDATIONS 
In order to curtail the spread of HIV/AIDS and to effectively manage those already infected, 
the following measures are suggested; 
- There should be an intensification of public awareness campaign on HIV/AIDS;  
- More voluntary counseling and testing (VCT), and treatment centre should be 
established, especially in the rural areas; 
- There should be a legalization against discrimination of people living with 
HIV/AIDS; 
- All aspects of HIV/AIDS management including laboratory services and drugs should 
be made free; 
-  All the three (3) classes of antiretroviral drugs including the protease inhibitors 
should be made available; 
- Adherence counseling should be given to patients before initiation of therapy and at 
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every clinic visit;  
- Patients evaluation tests such as CD4 count, liver function test (LFT), plasma HIV 
RNA, full blood count and basic chemical test should be performed at stated intervals;  
- Efforts should be intensified to get a permanent cure for HIV/AIDS. 
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Figure1. Bar chart showing patients categorization based on clinical staging 
system.  
 
Table 1. Analysis of patient CD4 count at Baseline. 
CD4 count (cells/µL) Frequency Percent 
1-50 20 35.71 
51-100 10 17.86 
101-150 17 30.35 
151-200 7 12.50 
201-250 1  1.79 
251-300 1 1.79 
Total 56 100.00 
 
Data  extracted from the patients’ case  notes obtained from the Medical Records department 
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Table 2. HAART Regimen used as first line 
Regimen Frequency Percent  
d4T/3TC/NEV 
d4T/3TC/EFV 
Total 
54 
8 
62 
87.10 
12.90 
100.00 
 
Data  extracted from the patients’ case  notes obtained from the Medical Records department 
 
Table 3. Co-Infections and co-morbidities reviewed. 
Disease Frequency Percent 
Co-Infection 
Candidiasis  
 
7 
 
11.30 
Malaria 22 35.48 
Pulmonary 
tuberculosis 
8 13.00 
Upper respiratory tract 
infections 
9 14.52 
Others 9 14.52 
Co-morbidity 
Hypertension 
 
12 
 
19.35 
Data  extracted from the patients’ case  notes obtained from the Medical Records department 
 
TABLE 4. CONCOMITANT DRUGS PRESCRIBED 
Class of Drug Frequency of  prescriptions 
Antibacterials 111 
Analgesics 22 
Antimalarials 37 
Antihistamines 23 
Antihypertensives 45 
Antimicrobials 12 
Antifungals (oral) 6 
Benzodiazepines 7 
Multivitamins/ Minerals 78 
Other drugs 41 
 
Data  extracted from the patients’ case  notes obtained from the Medical Records department 
 
Table 5. Possible interactions between concurrent drugs and ARVs 
prescribed 
Drug ARV Frequency Percent 
Fluconazole Nevirapine 6 9.68 
Isoniazid Stavudine 8 13.00 
Cotrimoxazole Lamivudine 62 100.00 
Rifampicin Nevirapine 1 1.61 
 
Data  extracted from the patients’ case  notes obtained from the Medical Records department 
 
 
Table 6. Documented Adverse Effects 
15 
 
Adverse Effect Frequency Percent 
Pain 12 19.35 
Diarrhoea 9 14.52 
Weakness/Fatigue 3 4.84 
Hallucinations 1 1.61 
Headache 3 4.84 
Insomnia 7 11.29 
Itching 13 20.97 
Paraesthesia 6 9.68 
Peripheral neuropathy 2 3.23 
Rash 10 16.13 
Stevens Johnson Syndrome 1 1.61 
Hearing loss 1 1.61 
Vomiting 3 4.84 
Data  extracted from the patients’ case  notes obtained from the Medical Records department 
 
Table 7. Change in patient CD4 count 6-12 months after initiation of 
HAART (n=35). 
Patient 
No 
Age 
(years) 
Gender CD4 count (cells/µL) 
   Baseline 6-12 
months 
Difference 
1 
2 
30 
52 
F 
M 
160 
4 
499 
119 
339 
115 
3 39 F 94 133 39 
4 28 M 15 18 3 
5 40 M 124 269 145 
6 32 F 126 424 298 
7 36 F 114 139 25 
8 52 F 146 334 188 
9 31 F 33 119 86 
10 30 F 30 269 239 
11 32 M 147 182 35 
12 33 F 189 510 321 
13 42 M 278 482 204 
14 39 M 14 206 192 
15 40 M 143 267 124 
16 45 F 50 145 95 
17 41 M 17 264 247 
18 37 M 75 41 -34 
19 53 F 39 173 134 
20 42 M 50 185 135 
21 30 F 20 204 184 
22 28 F 126 392 266 
23 34 M 29 140 111 
24 40 M 105 452 347 
25 27 F 111 316 205 
26 25 F 177 394 217 
27 40 F 212 313 101 
28 16 M 56 64 8 
16 
 
29 30 F 11 118 107 
30 30 F 104 302 198 
31 30 F 98 230 132 
32 26 F 183 436 253 
33 58 F 78 352 274 
34 30 F 139 487 348 
35 50 F 147 388 241 
 
• Abbreviations, M-male, F-female 
• Data  extracted from the patients’ case  notes obtained from the Medical Records 
department 
 
